NCT02508246View on ClinicalTrials.gov

WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 22, 2015

Primary Completion Date

April 26, 2018

Study Completion Date

April 26, 2018

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG

Cisplatin

Given IV

DRUG

Docetaxel

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

DRUG

WEE1 Inhibitor AZD1775

Given PO

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT02508246 - WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck | Biotech Hunter | Biotech Hunter